Development Of A Dual Inhibitor Targeting Hmg-Coa Reductase And Histone Deacetylase Rescues Neurite Degeneration In Lrrk2-G2019s Parkinsonism

Background: Parkinson’s disease (PD) is a neurodegenerative disorder lacking a disease-modifying therapy. Leucine-rich repeat kinase 2 (LRRK2) was implicated as the most common genetic cause of PD and the clinical phenotypes of LRRK2 mutation carriers are similar with late-onset sporadic PD patients. Statins, which are HMG-CoA reductase (HMGR) inhibitors, and histone deacetylase (HDAC) inhibitors are both found to have neuroprotective effects.